p-IGF-1 Receptor/IGF1R Antibody (50.Y1165/1166): sc-135767

p-IGF-IR Antibody (50.Y1165/1166) is a mouse monoclonal IgG1 antibody that detects insulin-like growth factor-I receptor (IGF-IR) in human samples through applications such as western blotting (WB) and enzyme-linked immunosorbent assay (ELISA). Anti-IGF-IR antibody (50.Y1165/1166) plays a crucial role in studying IGF-IR function, a receptor tyrosine kinase integral to various cellular processes, including growth, survival, and differentiation. IGF-IR is primarily located on the cell membrane, where IGF-IR acts as a transmembrane molecular scaffold facilitating insulin-like growth factor-I (IGF-I) binding. This interaction triggers downstream signaling pathways that influence cell proliferation and metabolism, making IGF-IR essential in both normal physiological processes and pathological conditions, such as cancer. IGF-IR′s ability to block apoptosis and promote cell growth underscores IGF-IR′s importance in tumorigenesis, as aberrant IGF-IR signaling can lead to uncontrolled cell division and survival. Understanding IGF-IR dynamics and interactions with other signaling molecules is essential for developing targeted therapies in cancer treatment and other diseases associated with dysregulated growth factor signaling.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-IGF-1 Receptor/IGF1R Antibody (50.Y1165/1166) References:

1. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.  |  Maloney, EK., et al. 2003. Cancer Res. 63: 5073-83. PMID: 12941837
2. Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival.  |  Catrina, SB., et al. 2005. Br J Cancer. 92: 1467-74. PMID: 15812560
3. Activation of insulin-like growth factor I receptor-mediated pathway by ginsenoside Rg1.  |  Chen, WF., et al. 2006. Br J Pharmacol. 147: 542-51. PMID: 16415910
4. Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.  |  Stoeltzing, O., et al. 2007. Cancer Lett. 258: 291-300. PMID: 17950526
5. Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer.  |  Chakravarty, G., et al. 2009. Exp Biol Med (Maywood). 234: 372-86. PMID: 19176870
6. Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.  |  Carver, KC., et al. 2010. J Biol Chem. 285: 8003-12. PMID: 20080972
7. Purification of insulin-like growth factor I receptor from human placental membranes.  |  LeBon, TR., et al. 1986. J Biol Chem. 261: 7685-9. PMID: 3011795
8. Involvement of Src-homology/collagen (SHC) proteins in signaling through the insulin receptor and the insulin-like-growth-factor-I-receptor.  |  Giorgetti, S., et al. 1994. Eur J Biochem. 223: 195-202. PMID: 8033892
9. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis.  |  D'Ambrosio, C., et al. 1996. Cancer Res. 56: 4013-20. PMID: 8752172
10. Insulin-like growth factor-I receptor and insulin receptor association with a Src homology-2 domain-containing putative adapter.  |  Wang, J. and Riedel, H. 1998. J Biol Chem. 273: 3136-9. PMID: 9452421

The preferred INSR/Insulin Receptor β antibody is INSR/Insulin Receptor β Antibody (CT-3): sc-57342.